MicroRNAs in the p53 network: Micromanagement of tumour suppression

Nature Reviews Cancer

Volumn 12, Issue 9, 2012, Pages 613-626

  Hermeking, Heiko ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E; CYCLIN E2; DICER; DICER 1 PROTEIN; KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 107; MICRORNA 130B; MICRORNA 143; MICRORNA 145; MICRORNA 15A; MICRORNA 16; MICRORNA 192; MICRORNA 200C; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MYC PROTEIN; PROTEIN P53; PROTEIN P63; RNA BINDING MOTIF PROTEIN 38; RNA BINDING PROTEIN; SMALL UNTRANSLATED RNA; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE G1 PHASE; CELL CYCLE PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC TEST; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE DELETION; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE REPRESSION; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; METASTASIS; NEOPLASM; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; RNA PROCESSING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866423871     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3318     Document Type: Review

References (182)

1. Friedman, R. C., Farh, K. K., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92-105 (2009).
2. Lujambio, A. & Lowe, S. W. The microcosmos of cancer. Nature 482, 347-355 (2012).
3. Spizzo, R., Nicoloso, M. S., Croce, C. M. & Calin, G. A. SnapShot: microRNAs in cancer. Cell 137, 586-586. e1 (2009).
4. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
5. Ravi, A. et al. Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell 21, 848-855 (2012).
6. Leung, A. K. & Sharp, P. A. microRNAs: a safeguard against turmoil? Cell 130, 581-585 (2007).
7. Leung, A. K. & Sharp, P. A. MicroRNA functions in stress responses. Mol. Cell 40, 205-215 (2010).
8. Soussi, T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv. Cancer Res. 110, 107-139 (2011).
9. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
10. Vaseva, Angelina, V. et al. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149, 1536-1548 (2012).
11. Menendez, D., Inga, A. & Resnick, M. A. The expanding universe of p53 targets. Nature Rev. Cancer 9, 724-737 (2009).
12. Riley, T., Sontag, E., Chen, P. & Levine, A. Transcriptional control of human p53-regulated genes. Nature Rev. Mol. Cell Biol. 9, 402-412 (2008).
13. Rinn, J. L. & Huarte, M. To repress or not to repress: this is the guardian's question. Trends Cell Biol. 21, 344-353 (2011).
14. Kruse, J. P. & Gu, W. Modes of p53 regulation. Cell 137, 609-622 (2009).
15. Hermeking, H. The 14-3-3 cancer connection. Nature Rev. Cancer 3, 931-943 (2003).
16. Hermeking, H. p53 enters the microRNA world. Cancer Cell 12, 414-418 (2007).
17. Hermeking, H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 17, 193-199 (2010).
18. Vousden, K. H. & Ryan, K. M. p53 and metabolism. Nature Rev. Cancer 9, 691-700 (2009).
19. Mendell, J. T. & Olson, E. N. MicroRNAs in stress signaling and human disease. Cell 148, 1172-1187 (2012).
20. Ebert, M. S. & Sharp, P. A. Roles for MicroRNAs in conferring robustness to biological processes. Cell 149, 515-524 (2012).
21. Suzuki, H. I. et al. Modulation of microRNA processing by p53. Nature 460, 529-533 (2009).
22. Kumar, M. S. et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 23, 2700-2704 (2009).
23. Mudhasani, R. et al. Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence in primary cells. J. Cell Biol. 181, 1055-1063 (2008).
24. Su, X. et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467, 986-990 (2010).
25. Leveille, N. et al. Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nature Commun. 2, 513 (2011).
26. Tarasov, V. et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6, 1586-1593 (2007).
27. He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134 (2007).
28. Raver-Shapira, N. et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26, 731-743 (2007).
29. Chang, T. C. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26, 745-752 (2007).
30. Bommer, G. T. et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17, 1298-1307 (2007).
31. Corney, D. C., Flesken-Nikitin, A., Godwin, A. K., Wang, W. & Nikitin, A. Y. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67, 8433-8438 (2007).
32. Kaller, M. et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and micro-array analysis. Mol. Cell. Proteomics 10, M111.010462 (2011).
33. Lal, A. et al. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 7, e1002363 (2011).
34. Sachdeva, M. et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl Acad. Sci. USA 106, 3207-3212 (2009).
35. Zhu, H. et al. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol. Cancer Res. 9, 960-975 (2011).
36. Ragimov, N. et al. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8, 1183-1193 (1993).
37. Hermeking, H. & Eick, D. Mediation of c-Myc-induced apoptosis by p53. Science 265, 2091-2093 (1994).
38. Lodygin, D. et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7, 2591-2600 (2008).
39. Choi, Y. J. et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nature Cell Biol. 13, 1353-1360 (2011).
40. Fabbri, M. et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305, 59-67 (2011).
41. Klein, U. et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28-40 (2010).
42. Calin, G. A. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002).
43. Bohlig, L. Friedrich, M. & Engeland, K. p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. Nucleic Acids Res. 39, 440-453 (2011).
44. Staton, A. A., Knaut, H. & Giraldez, A. J. miRNA regulation of Sdf1 chemokine signaling provides genetic robustness to germ cell migration. Nature Genet. 43, 204-211 (2011).
45. Georges, S. A. et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res. 68, 10105-10112 (2008).
46. Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292 (2011).
47. Chang, C. J. et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biol. 13, 317-323 (2011).
48. Kim, T. et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 208, 875-883 (2011).
49. Burk, U. et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582-589 (2008).
50. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biol. 10, 593-601 (2008).
51. Korpal, M., Lee, E. S., Hu, G. & Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910-14914 (2008).
52. Park, S. M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894-907 (2008).
53. Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
54. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biol. 11, 1487-1495 (2009).
55. Neves, R. et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res. Notes 3, 219 (2010).
56. Eades, G. et al. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J. Biol. Chem. 286, 25992-26002 (2011).
57. Siemens, H. et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10, 4256-4271 (2011).
58. Kim, N. H. et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol. 195, 417-433 (2011).
59. Brabletz, T. MiR-34 and SNAIL: another double-negative feedback loop controlling cellular plasticity/EMT governed by p53. Cell Cycle 11, 215 (2012).
60. Dave, N. et al. Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. J. Biol. Chem. 286, 12024-12032 (2011).
61. Toyota, M. et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 68, 4123-4132 (2008).
62. Vogt, M. et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 458, 313-322 (2011).
63. Lujambio, A. et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. USA 105, 13556-13561 (2008).
64. Liu, C. et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Med. 17, 211-215 (2011).
65. Hwang, C. I. et al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc. Natl Acad. Sci. USA 108, 14240-14245 (2011).
66. Mudduluru, G. et al. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 30, 2888-2899 (2011).
67. Martello, G. et al. A MicroRNA targeting dicer for metastasis control. Cell 141, 1195-1207 (2010).
68. Li, X. et al. MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer. J. Cell. Mol. Med. 15, 1887-1895 (2011).
69. Tapia, N. & Scholer, H. R. p53 connects tumorigenesis and reprogramming to pluripotency. J. Exp. Med. 207, 2045-2048 (2010).
70. Krizhanovsky, V. & Lowe, S. W. Stem cells: the promises and perils of p53. Nature 460, 1085-1086 (2009).
71. Jain, A. K. et al. p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. PLoS Biol. 10, e1001268 (2012).
72. Kim, N. H. et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci. Signal. 4, ra71 (2011).
73. Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
74. Ji, Q. et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4, e6816 (2009).
75. Xu, N., Papagiannakopoulos, T., Pan, G., Thomson, J. A. & Kosik, K. S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137, 647-658 (2009).
76. Suh, S. O. et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 32, 772-778 (2011).
77. Gan, B. et al. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 18, 472-484 (2010).
78. Brabletz, S. et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 30, 770-782 (2011).
79. Vallejo, D. M., Caparros, E. & Dominguez, M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J. 30, 756-769 (2011).
80. Yamakuchi, M., Ferlito, M. & Lowenstein, C. J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl Acad. Sci. USA 105, 13421-13426 (2008).
81. Schickel, R., Park, S. M., Murmann, A. E. & Peter, M. E. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol. Cell 38, 908-915 (2010).
82. Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944-13949 (2005).
83. Pichiorri, F. et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18, 367-381 (2010).
84. Vega, S. et al. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 18, 1131-1143 (2004).
85. Rottiers, V. & Näär, A. M. MicroRNAs in metabolism and metabolic disorders. Nature Rev. Mol. Cell Biol. 13, 239-250 (2012).
86. DeBerardinis, Ralph, J. & Thompson, Craig, B. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148, 1132-1144 (2012).
87. Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg's contributions to current concepts of cancer metabolism. Nature Rev. Cancer 11, 325-337 (2011).
88. Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283 (2012).
89. Li, W. Q. et al. The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J. 278, 1522-1532 (2011).
90. Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425-434 (2006).
91. Dang, C. V., Kim, J. W., Gao, P. & Yustein, J. The interplay between MYC and HIF in cancer. Nature Rev. Cancer 8, 51-56 (2008).
92. Menssen, A. et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc. Natl Acad. Sci. USA 109, e187-e196 (2012).
93. Zhu, H. et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 147, 81-94 (2011).
94. Yamakuchi, M. et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc. Natl Acad. Sci. USA 107, 6334-6339 (2010).
95. Roybal, J. D. et al. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol. Cancer Res. 9, 25-35 (2011).
96. Panda, H. et al. Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKKβ, KLF9, and FBLN5. Reprod. Sci. 8 May 2012 (doi:10.1177/ 1933719112438448).
97. Yan, H. L. et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J. 28, 2719-2732 (2009).
98. Le, M. T. N. et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 23, 862-876 (2009).
99. Le, M. T. et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet. 7, e1002242 (2011).
100. Nishida, N. et al. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int. J. Oncol. 38, 1437-1443 (2011).
101. Enomoto, Y. et al. Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 25, 1849-1856 (2011).
102. Zhang, Y. et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 71, 3552-3562 (2011).
103. Hu, W. et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol. Cell 38, 689-699 (2010).
104. Herrera-Merchan, A. et al. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 9, 3277-3285 (2010).
105. Tian, S. et al. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3? untranslated region. Biochem. Biophys. Res. Commun. 396, 435-439 (2010).
106. Swarbrick, A. et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nature Med. 16, 1134-1140 (2010).
107. Kumar, M. et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 30, 843-853 (2011).
108. Li, N. et al. A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res. 72, 154-164 (2012).
109. Chen, Q. R. et al. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J. Proteome Res. 10, 479-487 (2011).
110. Lize, M., Klimke, A. & Dobbelstein, M. MicroRNA-449 in cell fate determination. Cell Cycle 10, 2874-2882 (2011).
111. Bou Kheir, T. et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol. Cancer 10, 29 (2011).
112. Fornari, F. et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 69, 5761-5767 (2009).
113. Burns, D. M., D'Ambrogio, A., Nottrott, S. & Richter, J. D. CPEB and two poly(A) polymerases control miR-122 stability and p53 mRNA translation. Nature 473, 105-108 (2011).
114. Braun, C. J. et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 68, 10094-10104 (2008).
115. Xiao, J., Lin, H., Luo, X. & Wang, Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J. 30, 524-532 (2011).
116. Park, S.-Y., Lee, J. H., Ha, M., Nam, J.-W. & Kim, V. N. miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nature Struct. Mol. Biol. 16, 23-29 (2009).
117. Ugalde, A. P. et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J. 30, 2219-2232 (2011).
118. Diederichs, S. & Haber, D. A. Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res. 66, 6097-6104 (2006).
119. Kuchenbauer, F. et al. In-depth characterization of the microRNA transcriptome in a leukemia progression model. Genome Res. 18, 1787-1797 (2008).
120. Mayr, C. & Bartel, D. P. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673-684 (2009).
121. Mayr, C., Hemann, M. T. & Bartel, D. P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315, 1576-1579 (2007).
122. Bui, T. V. & Mendell, J. T. Myc: maestro of microRNAs. Genes Cancer 1, 568-575 (2010).
123. Salmena, L., Poliseno, L., Tay, Y., Kats, L. & Pandolfi, P. P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146, 353-358 (2011).
124. Tay, Y. et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147, 344-357 (2011).
125. Melo, S. A. et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18, 303-315 (2010).
126. Melo, S. A. et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nature Genet. 41, 365-370 (2009).
127. Karube, Y. et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 96, 111-115 (2005).
128. Leaderer, D. et al. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int. J. Mol. Epidemiol. Genet. 2, 9-18 (2011).
129. Merritt, W. M. et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 2641-2650 (2008).
130. Rio Frio, T. et al. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA 305, 68-77 (2011).
131. Hill, D. A. et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 325, 965 (2009).
132. Prosser, H. M., Koike-Yusa, H., Cooper, J. D., Law, F. C. & Bradley, A. A resource of vectors and ES cells for targeted deletion of microRNAs in mice. Nature Biotech. 29, 840-845 (2011).
133. Dow, L. E. et al. A pipeline for the generation of shRNA transgenic mice. Nature Protoc. 7, 374-393 (2012).
134. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome-biological and translational implications. Nature Rev. Cancer 11, 726-734 (2011).
135. Kalimutho, M. et al. Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br. J. Cancer 104, 1770-1778 (2011).
136. Kamimae, S. et al. Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors. Cancer Prev. Res. 4, 674-683 (2011).
137. Feinberg, A. P., Ohlsson, R. & Henikoff, S. The epigenetic progenitor origin of human cancer. Nature Rev. Genet. 7, 21-33 (2006).
138. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
139. Kasinski, A. L. & Slack, F. J. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Rev. Cancer 11, 849-864 (2011).
140. Trang, P. et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19, 1116-1122 (2011).
141. Tivnan, A. et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE 7, e38129 (2012).
142. Fabian, M. R., Sonenberg, N. & Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351-379 (2010).
143. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
144. Bandi, N. & Vassella, E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol. Cancer 10, 55 (2011).
145. Chim, C. S. et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31, 745-750 (2010).
146. Corney, D. C. et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16, 1119-1128 (2010).
147. Kubo, T. et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin. Cancer Res. 17, 4965-4974 (2011).
148. Chen, X. et al. CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int. J. Cancer 130, 1607-1613 (2012).
149. Welch, C., Chen, Y. & Stallings, R. L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26, 5017-5022 (2007).
150. Gallardo, E. et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30, 1903-1909 (2009).
151. Rucker, F. G. et al. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia 19 Jul 2012 (doi:10.1038/leu.2012.208).
152. Suzuki, H. et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 31, 2066-2073 (2010).
153. Wang, Z. et al. DNA hypermethylation of microRNA-34b/c has prognostic value for stage non-small cell lung cancer. Cancer Biol. Ther. 11, 490-496 (2011).
154. Cai, K. M. et al. Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. Int. J. Mol. Med. 25, 565-571 (2010).
155. Leucci, E. et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J. Pathol. 216, 440-450 (2008).
156. Dong, F. & Lou, D. MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis 18, 537-546 (2012).
157. Calin, G. A. et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793-1801 (2005).
158. Bonci, D. et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Med. 14, 1271-1277 (2008).
159. Bandi, N. et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69, 5553-5559 (2009).
160. Amaral, F. C. et al. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J. Clin. Endocrinol. Metab. 94, 320-323 (2009).
161. Bhattacharya, R. et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 69, 9090-9095 (2009).
162. Bottoni, A. et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J. Cell. Physiol. 204, 280-285 (2005).
163. Zhang, X. J. et al. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J. Hematol. Oncol. 3, 46 (2010).
164. Musumeci, M. et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 30, 4231-4242 (2011).
165. Porkka, K. P. et al. The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer 50, 499-509 (2011).
166. Earle, J. S. et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J. Mol. Diagn. 12, 433-440 (2010).
167. Wong, T. S. et al. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin. Cancer Res. 14, 2588-2592 (2008).
168. Careccia, S. et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene 28, 4034-4040 (2009).
169. Lee, K. H. et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9, 293-301 (2009).
170. Pallasch, C. P. et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 114, 3255-3264 (2009).
171. Karaayvaz, M. et al. Prognostic significance of miR-215 in colon cancer. Clin. Colorectal Cancer 10, 340-347 (2011).
172. Kahlert, C. et al. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci. 102, 1799-1807 (2011).
173. Tellez, C. S. et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 71, 3087-3097 (2011).
174. Ceppi, P. et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol. Cancer Res. 8, 1207-1216 (2010).
175. Wiklund, E. D. et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 128, 1327-1334 (2011).
176. Du, Y. et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J. Gastroenterol. 44, 556-561 (2009).
177. Vrba, L. et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 5, e8697 (2010).
178. Hu, X. et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol. Oncol. 114, 457-464 (2009).
179. Davalos, V. et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31, 2062-2074 (2011).
180. Hur, K. et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 10 Jul 2012 (doi:10.1136/gutjnl-2011-301846).
181. Kim, M. S. et al. Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers. J. Pathol. 221, 139-146 (2010).
182. Bousquet, M. et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J. Exp. Med. 205, 2499-2506 (2008).